NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...
Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...
NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...
Nearly 30,000 people in England living with chronic obstructive pulmonary disease could see their lives transformed after the ...
A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...
The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...
FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 2026 GOLD report newly highlights disease activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results